Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (racemetyrosine) late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in prostate, breast and hematological cancers.

Event: Jefferies Virtual Global Healthcare Conference
Place: Waldorf Hilton, London
Presentation Date: November 17-19, 2020
Format: One-on-one sessions

The presentation will be accessible on the events page under the investor relations section of Tyme Technologies’ website at www.tymeinc.com.

About SM-88

SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. Learn more.

About TYME-18

TYME-18 is composed of a proprietary surfactant delivery agent with a specific sulfonic acid component. It is designed for intra-tumoral administration of difficult to treat tumors and leverages the acidic tumor microenvironment and signaling pathways to kill cancer cells. TYME-18 is distinct in composition, but like SM-88, aims to leverage susceptibilities of a cancer that are related to its altered metabolism. Initial preclinical data for TYME-18 in animal tumor models demonstrate rapid and complete tumor regression, with no reported local or systemic toxicities. TYME-18 continues to be studied as a potential therapy for difficult to treat tumors that may not be eligible for surgical or other interventions. Learn more.

About TYME-19

TYME-19 is a potent, well characterized synthetic antiviral bile acid that is being evaluated as a potential oral therapy for COVID-19. In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity in treated cells. COVID-19 hijacks a cell’s ability to make proteins and lipids and divert these processes to make viral proteins and lipids in order to reproduce. COVID-19 accomplishes this by inducing stress in the endoplasmic reticulum (ER), where cells process proteins, which enables the virus to remodel protein and lipid synthesis. In preclinical testing, TYME-19 has been shown to counteract these effects, preventing viral replication, by reducing ER stress. TYME-19 is believed to physically degrade viruses by solubilizing the protective lipid layer and other structural components, which prevent a virus from binding to and infecting a cell.

About TYME-88-Panc Pivotal Trial

The TYME-88-Panc pivotal trial applies the latest advances in the field of cancer metabolism by evaluating the efficacy and safety of an oral investigational compound that targets the metabolic mechanisms of the

Zebra Technologies Empowers Interdisciplinary Care with Innovative Healthcare Offerings

New purpose-built scanner and mobile computers help restore caregivers’ time and purpose

Zebra Technologies Corporation (NASDAQ: ZBRA), an innovator at the front line of business with solutions and partners that deliver a performance edge, today announced new healthcare solutions designed to enable positive patient identification, increase operational efficiencies, and deliver improved patient care. The new purpose-built CS60-HC Series scanner and TC21-HC and TC26-HC mobile computers further Zebra’s ongoing commitment to serve the needs of hospitals and integrated delivery systems, with the goal of improving delivery of care.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005096/en/

Zebra Technologies Empowers Interdisciplinary Care with Innovative Healthcare Offerings (Photo: Business Wire)

Featuring a unique convertible design and disinfectant-ready housing built to withstand aggressive infection control procedures, the CS60-HC companion scanner adapts to changing workflow needs including corded, cordless, handheld and hands-free. This versatility reduces investment risk, as scanners can be easily redeployed to a cordless or corded application as clinical needs change. When used as a cordless scanner, the ultra-portable and pocketable CS60-HC supports nurse-carry workflows such as positive patient identification and medication administration.

As a corded scanner, it can be used in pharmacies, lab stations or other healthcare environment applications such as medication dispensary, electronic medical record access and specimen verification and reporting. The CS60-HC companion scanner includes Zebra’s DataCapture DNA suite of productivity, management, application development and visibility tools including Blood Bag Parse+, instantly capturing and parsing barcode data on blood bags in one trigger pull.

Zebra’s new TC21-HC and TC26-HC mobile computers increase communication and collaboration while helping deliver improved patient care. The new mobile computers are also ideal for connecting alternative caregivers and interdisciplinary teams that provide patient transport, facilities and materials management, biomedical engineering and security services with one another and with clinicians. The TC21-HC and TC26-HC, featuring Android 10, provide a familiar user-interface. They are made with disinfectant-ready housing – purpose-built for healthcare environments – to help ensure providers can safely and frequently disinfect their devices to reduce the risk of spreading healthcare associated infections (HAIs) in their facilities. In addition, the TC26-HC is Zebra’s first healthcare Wide Area Network (WAN) device with cellular capabilities, allowing both clinical and non-clinical teams to remain connected where seamless WiFi coverage is not available, such as large campuses, home health, and alternative care facilities.

“Increasing patient demands are driving clinicians to look for ways to improve workflow efficiency and communication at the point-of-care with patient safety and comfort in mind,” said Chris Sullivan, Global Healthcare Practice Lead, Zebra Technologies. “Zebra’s new scanning and mobility solution offerings help providers equip their clinicians with the tools they need to respond to patient needs in real-time while reducing workarounds that detract caregivers from their primary goals and often cause fatigue and burnout.”

The TC21-HC and TC26-HC mobile computers offer the powerful complimentary Mobility DNA software suite pre-loaded and ready to use, making it easier to stage, secure, troubleshoot and optimize devices in the hands of both clinicians and IT.

Schwazze, Formerly Operating as Medicine Man Technologies, Inc., Provides Update on Acquisition Strategy

DENVER–(BUSINESS WIRE)–Sep 30, 2020–

Schwazze, formerly operating as Medicine Man Technologies Inc. (OTCQX: SHWZ) (“Schwazze ” or “the Company”), a leading vertically-integrated Colorado cannabis company, today provided an update on its acquisition strategy.

The Company announced the termination of previously named term sheet with MedPharm Holdings, a cannabis research and development operator, which expired today, September 30, 2020. As noted earlier this year, the Company had moved forward on numerous term sheets with Colorado cannabis operators but had completed limited due diligence at that time. After the rigorous review and vetting process of MedPharm, the Company was unable to reach a mutually beneficial agreement to acquire MedPharm.

Justin Dye, Chairman and Chief Executive Officer of Schwazze shared, “The decision to terminate the binding term sheet with MedPharm is the right step forward for Schwazze. We are committed to creating shareholder value and generating compelling investment returns and believe that by staying true to our core business strategy of building a vertically integrated platform, we will do just that. Our focus remains unchanged, as our intention is to bring together profitable cannabis operators while growing organically to create a robust, differentiated and most admired cannabis company.”

Schwazze reiterated its commitment to establishing a leading vertically integrated cannabis platform. To accomplish this, the Company has acquired Mesa Organics, a dispensary chain with four locations in Southern Colorado, Purplebee’s a leading extraction and manufacturing business and remains on track to acquire the 14 Colorado locations of Star Buds which includes 13 retail locations and a cultivation facility. The Company will continue to make decisions that uniquely position Schwazze to provide the most trusted products and experiences for consumers and the best value for shareholders. The Company remains in negotiations with the announced acquisitions Roots Rx and Canyon Cultivation.

For more information about Schwazze, please visit https://www.Schwazze.com/.

About Schwazze

Medicine Man Technologies, Inc. is now operating under its new trade name, Schwazze. Schwazze (OTCQX: SHWZ) is executing its vision to become a leading vertically integrated cannabis holding company with a portfolio consisting of top-tier licensed brands spanning cultivation, extraction, infused-product manufacturing, dispensary operations, consulting, and a nutrient line. Schwazze leadership includes Colorado cannabis leaders with proven expertise in product and business development as well as top-tier executives from Fortune 500 companies. As a leading platform for vertical integration, Schwazze is strengthening the operational efficiency of the cannabis industry in Colorado and beyond, promoting sustainable growth and increased access to capital, while delivering best-quality service and products to the end consumer. The corporate entity continues to be named Medicine Man Technologies, Inc.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual